Experimental central nervous system aspergillosis therapy: Efficacy, drug levels and localization, immunohistopathology, and toxicity

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 8, 2012, Pages 4439-4449

  Clemons, Karl V ^a,b,c   Schwartz, Julie A ^d   Stevens, David A ^a,b,c  

^a CALIFORNIA INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CHARLES RIVER LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; INTERCELLULAR ADHESION MOLECULE 1; PADGEM PROTEIN; VORICONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPERGILLUS FUMIGATUS; BRAIN; BRAIN CAPILLARY; CENTRAL NERVOUS SYSTEM ASPERGILLOSIS; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG DISTRIBUTION; HEART; IMMUNOPATHOLOGY; KIDNEY INFECTION; KIDNEY TUBULE; LIVER TOXICITY; LUNG; MALE; MONOCYTE; MOUSE; NEPHROSIS; NONHUMAN; PRIORITY JOURNAL; SAMPLING; THERAPY EFFECT; TOXICITY;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; BRAIN; CYCLOPHOSPHAMIDE; DEOXYCHOLIC ACID; DRUG COMBINATIONS; ECHINOCANDINS; ENDOTHELIAL CELLS; HEART; IMMUNOSUPPRESSION; INTERCELLULAR ADHESION MOLECULE-1; KIDNEY; LUNG; MALE; MICE; NEPHROSIS; NEUROASPERGILLOSIS; P-SELECTIN; PYRIMIDINES; TRIAZOLES;

EID: 84864387255     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06015-11     Document Type: Article

References (41)

1. Arning M, Kliche KO, Heer-Sonderhoff AH, Wehmeier A. 1995. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 38:459-465. (Pubitemid 26042075)
2. Boswell GW, Bekersky I, Buell D, Hiles R, Walsh TJ. 1998. Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats. Antimicrob. Agents Chemother. 42:263-268. (Pubitemid 28114429)
3. Chiller TM, et al. 2002. Development of a murine model of cerebral aspergillosis. J. Infect. Dis. 186:574-577. (Pubitemid 34876271)
4. Chiller TM, Sobel RA, Luque JC, Clemons KV, Stevens DA. 2003. Efficacy of amphotericin B or itraconazole in a murine model of central nervous system Aspergillus infection. Antimicrob. Agents Chemother. 47:813-815. (Pubitemid 36158122)
5. Clemons KV, Espiritu M, Parmar R, Stevens DA. 2005. Comparative efficacies of conventional amphotericin B, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob. Agents Chemother. 49:4867-4875. (Pubitemid 41778896)
6. Clemons KV, Parmar R, Martinez M, Stevens DA. 2006. Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis. J. Antimicrob. Chemother. 58:466-469. (Pubitemid 44294969)
7. Clemons KV, Schwartz JA, Stevens DA. 2011. Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis. Med. Mycol. 49:834-847.
8. Clemons KV, Sobel RA, Williams PL, Pappagianis D, Stevens DA. 2002. Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits. Antimicrob. Agents Chemother. 46:2420-2426. (Pubitemid 34793444)
9. Coisne C, et al. 2006. Differential expression of selectins by mouse brain capillary endothelial cells in vitro in response to distinct inflammatory stimuli. Neurosci. Lett. 392:216-220. (Pubitemid 41739628)
10. Darisipudi MN, Allam R, Rupanagudi KV, Anders HJ. 2011. Polyene macrolide antifungal drugs trigger interleukin-1β secretion by activating the NLRP3 inflammasome. PLoS One 6:e19588. doi:10.1371/journal.pone.0019588.
11. Denning DW, Clemons KV, Stevens DA. 1992. Quantitative preservation of viability of Aspergillus fumigatus. J. Med. Vet. Mycol. 30:485-488. (Pubitemid 23037958)
12. Denning DW, Stevens DA. 1990. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev. Infect. Dis. 12:1147-1201.
13. Dietrich JB. 2002. The adhesion molecule ICAM-1 and its regulation in relation with the blood-brain barrier. J. Neuroimmunol. 128:58-68.
14. D'Mello C, Le T, Swain MG. 2009. Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factor-α signaling during peripheral organ inflammation. J. Neurosci. 29:2089-2102.
15. Gallis HA, Drew RH, Pickard WW. 1990. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12:308-329. (Pubitemid 20118658)
16. Gershkovich P, et al. 2009. Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation. J. Antimicrob. Chemother. 64:101-108.
17. Groll AH, et al. 2000. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J. Infect. Dis. 182:274-282. (Pubitemid 30497814)
18. Hanson LH, Clemons KV, Denning DW, Stevens DA. 1995. Efficacy of oral saperconazole in systemic murine aspergillosis. J. Med. Vet. Mycol. 33:311-317.
19. Hanson LH, Stevens DA. 1992. Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion. Antimicrob. Agents Chemother. 36:486-488.
20. Hofer S, et al. 2008. Injury of the blood brain barrier and up-regulation of ICAM-1 in polymicrobial sepsis. J. Surg. Res. 146:276-281.
21. Imai J, Singh G, Fernandez B, Clemons KV, Stevens DA. 2005. Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model. J. Antimicrob. Chemother. 56:166-171. (Pubitemid 41418352)
22. Imai JK, Singh G, Clemons KV, Stevens DA. 2004. Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob. Agents Chemother. 48:4063-4066. (Pubitemid 39304651)
23. Lachin JM. 1999. Worst-rank score analysis with informatively missing observations in clinical trials. Control. Clin. Trials 20:408-422. (Pubitemid 29460918)
24. Leenders AC, de Marie S, ten Kate MT, Bakker-Woudenberg IA, Verbrugh HA. 1996. Liposomal amphotericin B (AmBisome) reduces dissemination of infection compared with amphotericin B deoxycholate (Fungizone) in a rat model of pulmonary aspergillosis. J. Antimicrob. Chemother. 38:215-225. (Pubitemid 26302582)
25. Lestner JM, et al. 2010. Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 54:3432-3441.
26. Louie A, Baltch AL, Franke MA, Smith RP, Gordon MA. 1994. Comparative capacity of four antifungal agents to stimulate murine macrophages to produce tumour necrosis factor alpha: an effect that is attenuated by pentoxifylline, liposomal vesicles, and dexamethasone. J. Antimicrob. Chemother. 34:975-987.
27. Mehta D, Malik AB. 2006. Signaling mechanisms regulating endothelial permeability. Physiol. Rev. 86:279-367.
28. Munoz P, Guinea J, Narbona MT, Bouza E. 2008. Treatment of invasive fungal infections in immunocompromised and transplant patients: AmBiLoad trial and other new data. Int. J. Antimicrob. Agents 32(Suppl 2):S125-S131.
29. Murray HW. 2000. Mononuclear cell recruitment, granuloma assembly, and response to treatment in experimental visceral leishmaniasis: intracellular adhesion molecule 1-dependent and -independent regulation. Infect. Immun. 68:6294-6299.
30. Olson JA, et al. 2010. Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infections. Antimicrob. Agents Chemother. 54:3884-3894.
31. Prendergast CT, Anderton SM. 2009. Immune cell entry to central nervous system - current understanding and prospective therapeutic targets. Endocr. Metab. Immune Disord. Drug Targets 9:315-327.
32. Rogers PD, Pearson MM, Cleary JD, Sullivan DC, Chapman SW. 2002. Differential expression of genes encoding immunomodulatory proteins in response to amphotericin B in human mononuclear cells identified by cDNA microarray analysis. J. Antimicrob. Chemother. 50:811-817. (Pubitemid 36032799)
33. Rogers PD, Stiles JK, Chapman SW, Cleary JD. 2000. Amphotericin B induces expression of genes encoding chemokines and cell adhesion molecules in the human monocytic cell line THP-1. J. Infect. Dis. 182:1280-1283.
34. Shih W. 2002. Problems in dealing with missing data and informative censoring in clinical trials. Curr. Control Trials Cardiovasc. Med. 3:4.
35. Simitsopoulou M, et al. 2005. Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B. Antimicrob. Agents Chemother. 49:1397-1403. (Pubitemid 40463368)
36. Singh G, Imai J, Clemons KV, Stevens DA. 2005. Efficacy of caspofungin against central nervous system Aspergillus fumigatus infection in mice determined by TaqMan PCR and CFU methods. Antimicrob. Agents Chemother. 49:1369-1376. (Pubitemid 40463364)
37. Smith PJ, et al. 2007. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B. J. Antimicrob. Chemother. 59:941-951. (Pubitemid 47073366)
38. Tonomura Y, et al. 2009. Amphotericin B-induced nephrotoxicity: characterization of blood and urinary biochemistry and renal morphology in mice. Hum. Exp. Toxicol. 28:293-300.
39. Tucker R, Williams P, Arathoon E, Stevens D. 1988. Treatment of mycoses with itraconazole. Ann. N. Y. Acad. Sci. 544:451-470. (Pubitemid 19259359)
40. van de Stolpe A, van der Saag PT. 1996. Intercellular adhesion molecule-1. J. Mol. Med. 74:13-33.
41. Vonk AG, et al. 1998. Modulation of the pro- and anti-inflammatory cytokine balance by amphotericin B. J. Antimicrob. Chemother. 42:469-474. (Pubitemid 28473006)